Subscribe

Jacobson Pharma Corporation Limited (2633.HK)

HKD1.07 -0.01 (-0.93%)
HK HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address Tower 1, Millennium City 1
Kwun Tong, HK
CEO Kwong Yip Sum
Website jacobsonpharma.com
IPO 2016-09-21
ISIN KYG677291067

Explore sections of this company profile

Description

Jacobson Pharma Corporation Limited, a subsidiary of Kingshill Development Limited, specializes in the production, promotion, and distribution of generic medications and branded healthcare products. Its market reach extends across Hong Kong, mainland China, Macau, Singapore, and international territories. The company offers a broad selection of generic pharmaceuticals targeting diverse medical conditions, including respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergic, scar treatment, oral anti-diabetic, and anti-infective categories. Specific examples comprise arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. In addition to generics, the company provides branded medications, health and wellness products, and traditional Chinese remedies. Prominent proprietary Chinese medicines include Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. Its operations also extend to trading medical provisions, procuring packaging materials, distributing herbal and health-related goods, conducting research and development, and managing property holdings. The company distributes its offerings to a wide range of clients, including hospitals, clinics, authorized pharmacies, independent physicians, retail outlets, and trading companies. Founded in 2016, Jacobson Pharma Corporation Limited is headquartered in Kwun Tong, Hong Kong.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD1.07 -0.01 (-0.93%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
335.8K
Beta
0.22
Float Shares
379.80M
Free Float %
19.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.89% -0.88% +0.00% -11.02% -16.30% -13.08% -14.39% +25.56% +41.25% -32.74% -32.74%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.07
DCF (Unlevered) 5.45 +409.6%
DCF (Levered) 6.95 +549.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.22
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -0.5% Q1'26: +6.6% (vs Q1'24)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +0.0% Q1'26: +36.4% (vs Q1'24)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +26.5% ★ Q1'26: +21.7% (vs Q1'24)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +22.5% ★ Q1'26: +23.0% (vs Q1'24)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +10.2% ★ Q1'26: +21.6% (vs Q1'24)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.6% Q1'26: +3.6% (vs Q1'24)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    1.80× Q1'26: 0.87× (vs Q1'24)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.23) × ERP
WACC = 74% × Ke + 26% × Kd (5.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 5.47 Current price: 1.07
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana. 		Mar 2031
1 Rev. Ana.
1 EPS Ana. 		Mar 2032
1 Rev. Ana.
1 EPS Ana. 		Mar 2033
1 Rev. Ana.
1 EPS Ana. 		Mar 2034
1 Rev. Ana.
1 EPS Ana. 		Mar 2035
1 Rev. Ana.
1 EPS Ana. 		Mar 2036
1 Rev. Ana.
1 EPS Ana.
Revenue
1.26B
est: 1.23B (+2.1%)
1.55B
est: 1.63B (-4.8%)
1.48B
est: 1.72B (-13.9%)
1.57B
est: 1.57B (+0.0%)
1.45B
est: 1.71B (-15.3%)
1.60B
est: 1.84B (-13.2%)
1.79B
est: 1.97B (-9.2%)
1.47B
est: 1.56B (-6.0%)
1.58B
est: 1.97B (-19.8%)
1.55B
1.55B – 1.55B
-21.4% YoY
1.63B
1.63B – 1.63B
+5.6% YoY
1.73B
1.73B – 1.73B
+6.0% YoY
2.00B
2.00B – 2.00B
+15.8% YoY
1.71B
1.71B – 1.71B
-14.8% YoY
1.84B
1.84B – 1.84B
+7.8% YoY
1.97B
1.97B – 1.97B
+7.0% YoY
1.55B
1.55B – 1.55B
-21.4% YoY
1.63B
1.63B – 1.63B
+5.6% YoY
1.73B
1.73B – 1.73B
+6.0% YoY
2.00B
2.00B – 2.00B
+15.8% YoY
EBITDA
317.22M
est: 358.68M (-11.6%)
409.66M
est: 378.29M (+8.3%)
448.34M
est: 330.74M (+35.6%)
484.49M
est: 391.69M (+23.7%)
377.21M
est: 340.31M (+10.8%)
415.49M
est: 367.21M (+13.1%)
462.04M
est: 396.17M (+16.6%)
475.11M
est: 429.85M (+10.5%)
558.87M
est: 829.45M (-32.6%)
651.67M
651.67M – 651.67M
-21.4% YoY
688.31M
688.31M – 688.31M
+5.6% YoY
729.61M
729.61M – 729.61M
+6.0% YoY
844.74M
844.74M – 844.74M
+15.8% YoY
719.50M
719.50M – 719.50M
-14.8% YoY
775.42M
775.42M – 775.42M
+7.8% YoY
829.45M
829.45M – 829.45M
+7.0% YoY
651.67M
651.67M – 651.67M
-21.4% YoY
688.31M
688.31M – 688.31M
+5.6% YoY
729.61M
729.61M – 729.61M
+6.0% YoY
844.74M
844.74M – 844.74M
+15.8% YoY
EBIT
254.19M
est: 229.69M (+10.7%)
280.11M
est: 309.75M (-9.6%)
339.07M
est: 312.06M (+8.7%)
318.22M
est: 402.62M (-21.0%)
250.71M
est: 290.18M (-13.6%)
257.12M
est: 313.11M (-17.9%)
313.38M
est: 337.80M (-7.2%)
333.29M
est: 366.53M (-9.1%)
415.00M
est: 668.87M (-38.0%)
525.52M
525.52M – 525.52M
-21.4% YoY
555.06M
555.06M – 555.06M
+5.6% YoY
588.37M
588.37M – 588.37M
+6.0% YoY
681.20M
681.20M – 681.20M
+15.8% YoY
580.21M
580.21M – 580.21M
-14.8% YoY
625.30M
625.30M – 625.30M
+7.8% YoY
668.87M
668.87M – 668.87M
+7.0% YoY
525.52M
525.52M – 525.52M
-21.4% YoY
555.06M
555.06M – 555.06M
+5.6% YoY
588.37M
588.37M – 588.37M
+6.0% YoY
681.20M
681.20M – 681.20M
+15.8% YoY
Net Income
179.33M
est: 137.91M (+30.0%)
202.27M
est: 236.13M (-14.3%)
250.56M
est: 212.36M (+18.0%)
215.63M
est: 272.22M (-20.8%)
173.71M
est: 196.63M (-11.7%)
177.67M
est: 212.17M (-16.3%)
251.04M
est: 228.90M (+9.7%)
266.97M
est: 248.37M (+7.5%)
300.83M
est: 221.48M (+35.8%)
273.68M
273.68M – 273.68M
+23.6% YoY
315.63M
315.63M – 315.63M
+15.3% YoY
343.60M
343.60M – 343.60M
+8.9% YoY
453.47M
453.47M – 453.47M
+32.0% YoY
166.72M
166.72M – 166.72M
-63.2% YoY
194.71M
194.71M – 194.71M
+16.8% YoY
221.48M
221.48M – 221.48M
+13.7% YoY
273.68M
273.68M – 273.68M
+23.6% YoY
315.63M
315.63M – 315.63M
+15.3% YoY
343.60M
343.60M – 343.60M
+8.9% YoY
453.47M
453.47M – 453.47M
+32.0% YoY
SGA
303.99M
est: 296.12M (+2.7%)
339.23M
est: 438.98M (-22.7%)
341.13M
est: 356.90M (-4.4%)
401.85M
est: 370.62M (+8.4%)
407.59M
est: 366.44M (+11.2%)
400.13M
est: 395.41M (+1.2%)
426.90M
est: 426.59M (+0.1%)
332.38M
est: 462.86M (-28.2%)
324.24M
est: 444.04M (-27.0%)
348.87M
348.87M – 348.87M
-21.4% YoY
368.48M
368.48M – 368.48M
+5.6% YoY
390.59M
390.59M – 390.59M
+6.0% YoY
452.22M
452.22M – 452.22M
+15.8% YoY
385.18M
385.18M – 385.18M
-14.8% YoY
415.11M
415.11M – 415.11M
+7.8% YoY
444.04M
444.04M – 444.04M
+7.0% YoY
348.87M
348.87M – 348.87M
-21.4% YoY
368.48M
368.48M – 368.48M
+5.6% YoY
390.59M
390.59M – 390.59M
+6.0% YoY
452.22M
452.22M – 452.22M
+15.8% YoY
EPS
0.11
est: 0.07 (+58.4%)
0.11
est: 0.08 (+40.0%)
0.13
est: 0.08 (+58.1%)
0.11
est: 0.07 (+67.0%)
0.09
est: 0.08 (+8.7%)
0.09
est: 0.10 (-4.9%)
0.13
est: 0.11 (+17.3%)
0.07
est: 0.15 (-53.3%)
0.15
est: 0.11 (+35.3%)
0.14
0.14 – 0.14
+23.6% YoY
0.16
0.16 – 0.16
+15.3% YoY
0.17
0.17 – 0.17
+8.9% YoY
0.23
0.23 – 0.23
+32.0% YoY
0.08
0.08 – 0.08
-63.2% YoY
0.10
0.10 – 0.10
+16.8% YoY
0.11
0.11 – 0.11
+13.7% YoY
0.14
0.14 – 0.14
+23.6% YoY
0.16
0.16 – 0.16
+15.3% YoY
0.17
0.17 – 0.17
+8.9% YoY
0.23
0.23 – 0.23
+32.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-28 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-27 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-26 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-22 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-21 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-20 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-19 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-18 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-15 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-14 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-13 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-12 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-11 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-08 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-07 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-06 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-05 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-05-04 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-30 A 4/5 5/5 4/5 5/5 1/5 4/5 4/5
2026-04-29 A 4/5 5/5 4/5 5/5 1/5 4/5 4/5
2026-04-28 A 4/5 5/5 4/5 5/5 1/5 4/5 4/5
2026-04-27 A 4/5 5/5 4/5 5/5 1/5 4/5 4/5
2026-04-24 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-04-23 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-04-22 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-04-21 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-04-20 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-04-17 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-04-16 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
765.37M
OE per share TTM
0.39
Owner's Yield
33.93%
Maintenance CapEx ratio
13.05%
Maint CapEx / Avg PPE
89.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - International Small Cap ETF DFIS 0.00% 87.8K 0.39%
2 Dimensional - International Core Equity 2 ETF DFIC 0.00% 37.1K 0.22%
3 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 23.1K 0.28%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
204.2K
Shares Outstanding
2.00B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Kwong Yip Sum Chairman, Chief Executive Officer & Member of Scientific Advisory Committee 11M male
Chun Leung Yim FCCA Executive Director 4M male
Yue Wai Pun Vice President of Administration & Executive Director 2M female
Yu Sun Wong Executive Vice President of Operation Management — male
Kin Man Chan Vice President of Sales — male
Chun Kau Yu Chief Financial Officer & Company Secretary — male
Chi Shing Cheng Vice President of Human Resources — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic